Calliditas reveals results from vital NefIgArd study
Pharma Times
AUGUST 15, 2023
The study concerns the use of Nefecon among adult patients with primary IgA nephropathy - News - PharmaTimes
news iga-nephropathy 
95 
Sibeprenlimab’s Promising Phase II Results Lead to FDA Breakthrough Designation
XTalks
FEBRUARY 20, 2024
have announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for sibeprenlimab, an investigational drug intended for treating immunoglobulin A (IgA) nephropathy, commonly known as Berger’s disease. APRIL has been identified as a key driver of IgA and Gd-IgA1 production.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA advisors unconvinced by Reata’s kidney disease drug
pharmaphorum
DECEMBER 9, 2021
The news is also a massive disappointment to patients and their carers, as there are currently no FDA-approved therapies for Alport syndrome, which affects approximately 30,000 to 60,000 people in the US. .” Trading in Reata’s shares was halted ahead of the meeting, but the stock was down 38% pre-market this morning.
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis
The Pharma Data
APRIL 26, 2021
Iptacopan in IgA nephropathy met its primary endpoint in Ph2b enabling Ph3 initiation. Ph2 study in primary IgA nephropathy met the primary endpoint with efficacy and safety results supporting continuation into Ph3. 177 Lu-PSMA-617 Ph3 VISION study met both primary endpoints in patients with prostate cancer.
Let's personalize your content